Sumatriptan
- Atc Codes:N02CC01
- CAS Codes:103628-48-4#103628-46-2
- PHARMGKB ID:103628-48-4#103628-46-2
Table of contents
- Brand Names
- Drug Combinations
- Chemistry
- Pharmacologic Category
- Mechanism of Action
- Therapeutic Use
- Pregnancy and Lactation Implications
- Contraindications
- Warnings and Precautions
- Adverse Reactions
- Caution and personalized dose adjustment in patients with the following genotypes
- Other genes that may be involved
- Drug Interactions
- Nutrition/Nutraceutical Interactions
- Dosage
- Pharmacokinetics and Pharmacodynamics
- Special Considerations
Brand Names
Europe
Austria: Imigran, Sumatriptan; Belgium: Imitrex, Finigraine, Sumatriptan; Bulgaria: Amigren, Imigran, Sumatriptan; Cyprus: Imigran, Sumatad; Czech Republic: Cinie, Dolorstad, Imigran, Rosemig, Sumamigren, Sumatriptan, Sumigra; Denmark: Imigran; Sumatriptan; Estonia: Cinie, Illument, Imigran, Migriptan, Sumatriptan; Finland: Cinie, Imigran, Oriptan, Sumaratio, Sumatriptan; France: Imigrane, Imiject, Sumatriptan; Germany: Imigran, Imigrane, Imigranradis, Suma, Sumactalen, Sumadolaren, Sumaratio, Sumatrapt, Sumatres, Sumatripmed, Sumatriptan, Sumatriptil, Sumatrix, Sumy, Triptasum, Tripti; Greece: Altaxa, Forcet, Imigran, Notem, Precipitan, Sumatriptan, Sutriptan; Hungary: Cinie, Imigran, Migratriptan, Sumatriptan; Ireland: Imigran, Imitag, Migrastat, Sumatran, Sumatriptan, Suvalan, Triptagram; Italy: Imigran, Sumatriptan; Latvia: Cinie, Imigran, Sumatriptan; Lithuania: Cinie, Imigran, Illument, Migriptan, Sumatriptan; Luxembourg: Imitrex; Netherlands: Imigran, Sumalin, Sumarix, Sumatriptan; Poland: Amigrenex, Cinie, Dolorstad, Frimig, Illument, Imigran, Migropar, Sumagen, Sumamigren, Sumatriptan, Sumigra, Triptagram; Portugal: Imigran, Imigranradis, Sumatriptano; Romania: Imigran, Sumacta, Sumatriptan, Xibimer; Slovakia: Cinie, Imigran, Sumamigren, Sumatriptan; Slovenia: Imigran, Sumacta, Sumatriptan; Spain: Imigran, Sumatriptán; Sweden: Imigran, Oriptan, Sumatriptan, Triptamed, Zumo; UK: Imigran, Migraleve.
North America
Canada: Imitrex, Sumatriptan; USA: Alsuma, Imitrex, Sumatriptan Succinate, Sumavel Dosepro, Treximet.
Latin America
Argentina: Imigrán, Micranil, Migraneitor; Brazil: Imigran, Sumatriptana, Sumax; Mexico: Ferming, Imigrán, Sumitrex, Tebegrán.
Asia
Japan: Imigran.
Drug combinations
Sumatriptan and Naproxen
Chemistry
Sumatriptan Succinate: C~14~H~21~N~3~O~2~S C~4~H~6~O~4~. Mw: 413.49. (1) 1H-Indole-5-methanesulfonamide, 3-[2-(dimethylamino)ethyl]-N-methyl-, butanedioate (1:1); (2) 3-[2-(Dimethylamino)ethyl]-N-methylindole-5-methanesulfonamide succinate (1:1). CAS-103628-48-4; CAS-103628-46-2 (sumatriptan)(1989).
Pharmacologic Category
Antimigraine Agents; Selective Serotonin Agonists. Serotonin 5-HT~1B~, 5-HT~1D~ Receptor Agonist. (ATC-Code: N02CC01).
Mechanism of action
Binds with high affinity to 5-HT type 1-like receptors, probably 5-HT~1B~ and 5-HT~1D~ subtypes. May ameliorate migraine and cluster headache through selective constriction of certain large cranial blood vessels and/or inhibition of neurogenic inflammatory processes in CNS.
Therapeutic use
Acute treatment of migraine. Acute treatment of cluster headache episodes.
Pregnancy and lactiation implications
There are no adequate studies in pregnant women. Use only if potential benefit to mother outweighs potential risk to fetus. Enters breast milk (use with caution in nursing women).
Unlabeled use
Contraindications
Hypersensitivity to sumatriptan or any component of the formulation. Ischemic heart disease or signs or symptoms of ischemic heart disease. Cerebrovascular syndromes. Peripheral vascular syndromes. Uncontrolled hypertension. Use within 24 hours of ergotamine derivatives or another 5-HT~1~ agonist. Concurrent administration or within 2 weeks of discontinuing an MAOI, specifically MAO type A inhibitors. Hemiplegic or basilar migraine. Prophylactic treatment of migraine. Severe hepatic impairment. Not for I.V. administration.
Warnings and precautions
Coronary artery vasospasm, transient ischemia, myocardial infarction, ventricular tachycardia/fibrillation, cardiac arrest, and death reported with 5-HT~1~ agonist administration. Cerebral/subarachnoid hemorrhage and stroke reported with 5-HT~1~ agonist administration. Significant elevation in blood pressure, including hypertensive crisis reported. Peripheral vascular ischemia and colonic ischemia reported with 5-HT~1~ agonists. Should not be given to patients with risk factors for coronary artery disease (hypertension, hypercholesterolemia, smokers, obesity, diabetes, strong family history of coronary artery disease, menopause, male >40 years of age) without adequate cardiac evaluation. Use with caution in hepatic impairment, and in history of seizure disorder or in lowered seizure threshold. Serotonin syndrome (agitation, confusion, hallucinations, hyper-reflexia, myoclonus, shivering, and tachycardia) may occur with concomitant proserotonergic drugs (i.e. SSRIs/SNRIs or triptans) or agents which reduce metabolism of sumatriptan. Concurrent use of serotonin precursors (tryptophan) not recommended. Only indicated for treatment of migraine or cluster headache.